18.02.2021 | Correction
Correction to: Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study
- Zeitschrift:
- International Journal of Hematology
Wichtige Hinweise
The original article can be found online at https://doi.org/10.1007/s12185-020-03039-w.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
In the original publication of the article, the affiliation of the corresponding author “Miyako Hoshino” should be changed to “Japan Medical Office, Japan Pharma Business Unit, Takeda Pharmaceutical Co. Ltd., 1‑1, Nihonbashi‑Honcho 2‑chome, Chuo‑ku, Tokyo 103‑8668, Japan”. ...
